CDT (CDT Equity) Ending Cash Position: $1.51 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CDT CDT Equity Inc CDT
10 GF Score
Price $0.35
! 5 Warning Signs
View Full Analysis

What is CDT Equity Ending Cash Position?

CDT Equity CDT +0.34% 10 Ending Cash Position is $1.51 Mil as of Dec. 2025. GuruFocus rates CDT with a GF Score™ of 10/100. The stock has 5 warning signs investors should review.

CDT Equity's Ending Cash Position for the quarter that ended in Dec. 2025 was $1.51 Mil.

CDT Equity's quarterly Ending Cash Position increased from Jun. 2025 ($3.33 Mil) to Sep. 2025 ($3.84 Mil) but then declined from Sep. 2025 ($3.84 Mil) to Dec. 2025 ($1.51 Mil).

CDT Equity's annual Ending Cash Position declined from Dec. 2023 ($4.23 Mil) to Dec. 2024 ($0.55 Mil) but then increased from Dec. 2024 ($0.55 Mil) to Dec. 2025 ($1.51 Mil).

CDT Equity Ending Cash Position Related Terms

CDT Equity Ending Cash Position Historical Data

* Premium members only.

The historical data trend for CDT Equity's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CDT Equity Ending Cash Position Chart

CDT Equity Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
0.00 0.00 4.23 0.55 1.51

CDT Equity Quarterly Data
Dec21 Mar22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.55 2.13 3.33 3.84 1.51
CDT
10GF Score
CDT Equity Inc CDT
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CDT Equity Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

CDT Equity's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=0.554+0.955
=1.51

CDT Equity's Ending Cash Position for the quarter that ended in Dec. 2025 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=3.838+-2.329
=1.51

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $1.51 Mil mean?
CDT Equity (CDT) has a Ending Cash Position of $1.51 Mil as of Dec. 2025. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on CDT Equity and its competitors.
Is CDT Equity's Ending Cash Position too high?
CDT Equity's current Ending Cash Position is $1.51 Mil. Overall, CDT Equity has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does CDT Equity's Ending Cash Position compare to CLDI and DCOY?
CDT Equity's Ending Cash Position of $1.51 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on CDT Equity and its competitors. CDT Equity's current Ending Cash Position is $1.51 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CDT Equity stock overvalued right now?
CDT Equity (CDT) has a current Ending Cash Position of $1.51 Mil. The current Ending Cash Position is $1.51 Mil. CDT Equity's overall GF Score™ is 10/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For CDT Equity (CDT), the current Ending Cash Position is $1.51 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CDT Equity Business Description

Address 4581 Tamiami Trail North, Suite 200, Naples, FL, USA, 34103
CDT Equity Inc is a data-driven biopharmaceutical development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. It has evolved into a broader, more agile platform that leverages artificial intelligence, solid-form chemistry, and efficient asset repositioning to accelerate the development of novel treatments. The company's pipeline includes candidates that target autoimmune disorders, as well as idiopathic male infertility, oncology, dermatology, rare disease and animal health. It has one operating segment focused on the research and development of clinical assets.
10GF Score

Get the complete analysis for CDT

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.35
Price